Literature DB >> 32828382

Intensified Systemic Therapy Regimens in Combination With Definitive Radiation for Treatment of Cervical Cancer.

Travis T Sims1, Ann H Klopp2.   

Abstract

Definitive standard chemoradiation for locoregionally advanced carcinomas of the uterine cervix includes multimodality therapy consisting of concurrent cisplatin based chemoradiation comprising of external-beam radiotherapy with systemic chemotherapy followed by intracavitary brachytherapy. New developments in radiotherapy, such as intensity-modulated radiotherapy, which aim to improve tumor control rates and reduce associated toxicity have reopened the discussion regarding the benefit of intensification of concomitant or sequential systemic therapy in the treatment of cervical cancer. Intensification of systemic chemotherapy used in standard chemoradiation for cervical cancer is an attractive approach to improve disease control, but given the concerns regarding toxicity deserves further evaluation to ensure their safe use in patients. This is a review of published and ongoing studies investigating intensification of systemic chemotherapy in the treatment of locally advanced cervical cancer.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Year:  2020        PMID: 32828382      PMCID: PMC7869865          DOI: 10.1016/j.semradonc.2020.05.005

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  31 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer.

Authors:  Munetaka Takekuma; Yuka Kasamatsu; Nobuhiro Kado; Shiho Kuji; Aki Tanaka; Nobutaka Takahashi; Masakazu Abe; Yasuyuki Hirashima
Journal:  J Obstet Gynaecol Res       Date:  2015-07-14       Impact factor: 1.730

Review 3.  Cervical cancer worldwide.

Authors:  Mailinh Vu; Jim Yu; Olutosin A Awolude; Linus Chuang
Journal:  Curr Probl Cancer       Date:  2018-06-25       Impact factor: 3.187

4.  Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.

Authors:  Samantha Cabral S da Costa; Renata Colombo Bonadio; Flavia Carolina G Gabrielli; Andrea S Aranha; Maria Luiza N Dias Genta; Vanessa C Miranda; Daniela de Freitas; Elias Abdo Filho; Patrícia A O Ferreira; Karime K Machado; Mariana Scaranti; Heloísa de A Carvalho; Maria Del Pilar Estevez-Diz
Journal:  J Clin Oncol       Date:  2019-08-26       Impact factor: 44.544

5.  Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.

Authors:  Alfonso Dueñas-González; Juan J Zarbá; Firuza Patel; Juan C Alcedo; Semir Beslija; Luis Casanova; Pittayapoom Pattaranutaporn; Shahid Hameed; Julie M Blair; Helen Barraclough; Mauro Orlando
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

6.  A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study.

Authors:  A Sedlis; B N Bundy; M Z Rotman; S S Lentz; L I Muderspach; R J Zaino
Journal:  Gynecol Oncol       Date:  1999-05       Impact factor: 5.482

7.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

8.  Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.

Authors:  Michael F Milosevic; Carol A Townsley; Naz Chaudary; Blaise Clarke; Melania Pintilie; Stacy Fan; Rachel Glicksman; Masoom Haider; Sunmo Kim; Helen MacKay; Ivan Yeung; Richard P Hill; Anthony Fyles; Amit M Oza
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-09-18       Impact factor: 7.038

Review 9.  On the lack of demonstrated clinical benefit of neoadjuvant cisplatinum therapy for cervical cancer.

Authors:  R A Potish; L B Twiggs
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-11-15       Impact factor: 7.038

10.  Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix.

Authors:  J A Loncaster; R A Cooper; J P Logue; S E Davidson; R D Hunter; C M West
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.